Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    IMIPENEM; CILASTATIN

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 85960-17-4, Sodium;(z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, Imipenem + cilastatin, Imipenem-cilastatin sodium, Imipenem-cilastatin sodium mixt., Dtxsid60873393
    Molecular Formula
    C28H42N5NaO9S2
    Molecular Weight
    679.8  g/mol
    InChI Key
    VEVHCKVFLWYWCN-KJWPAVRRSA-M
    Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    sodium;(Z)-7-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate;(5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
    2.1.2 InChI
    InChI=1S/C16H26N2O5S.C12H17N3O4S.Na/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21;1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17;/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23);5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19);/q;;+1/p-1/b12-6-;;/t10-,11+;6-,7-,9-;/m11./s1
    2.1.3 InChI Key
    VEVHCKVFLWYWCN-KJWPAVRRSA-M
    2.1.4 Canonical SMILES
    CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O.CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)[O-])C.[Na+]
    2.1.5 Isomeric SMILES
    C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O.CC1(C[C@@H]1C(=O)N/C(=C\CCCCSC[C@@H](C(=O)O)N)/C(=O)[O-])C.[Na+]
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Cilastatin, Imipenem

    2. Cilastatin, Imipenem Drug Combination

    3. Imipenem - Cilastatin

    4. Imipenem - Cilastatin Sodium

    5. Imipenem Cilastatin

    6. Imipenem Cilastatin Sodium

    7. Imipenem Cilastatin, Sodium Salt

    8. Imipenem-cilastatin

    9. Imipenem-cilastatin Sodium

    10. Imipenem-cilastatin, Sodium Salt

    11. Mk 0787 Mk 0791 Mixture

    12. Mk 0787-mk 0791 Mixture

    13. Mk 787 Mk 791 Mixture

    14. Mk 787-mk 791 Mixture

    15. Primaxin

    16. Thienam

    17. Tienam 500

    18. Zienam

    2.2.2 Depositor-Supplied Synonyms

    1. 85960-17-4

    2. Sodium;(z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid

    3. Imipenem + Cilastatin

    4. Imipenem-cilastatin Sodium

    5. Imipenem-cilastatin Sodium Mixt.

    6. Dtxsid60873393

    7. Mfcd01744417

    8. Cilastatin Sodium Mixture With Imipenem

    9. Imipenem Combination With Cilastatin Sodium

    10. Mk-0787 / Mk-0791 (1:1)

    11. 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)amino)-7-oxo-, (5r-(5-alpha,6-alpha(r*)))-, Mixt. With (r-(r*,s*-(z)))-7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptenoic Acid Monosodium Salt

    2.3 Create Date
    2008-02-05
    3 Chemical and Physical Properties
    Molecular Weight 679.8 g/mol
    Molecular Formula C28H42N5NaO9S2
    Hydrogen Bond Donor Count6
    Hydrogen Bond Acceptor Count13
    Rotatable Bond Count17
    Exact Mass679.23216456 g/mol
    Monoisotopic Mass679.23216456 g/mol
    Topological Polar Surface Area299 Ų
    Heavy Atom Count45
    Formal Charge0
    Complexity1020
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Anti-Bacterial Agents

    Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

    Protease Inhibitors

    Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)

    4.2 FDA Pharmacological Classification
    4.2.1 Pharmacological Classes
    Dipeptidase Inhibitors [MoA]; Penem Antibacterial [EPC]; Renal Dehydropeptidase Inhibitor [EPC]; Carbapenems [CS]